NCT05721729Phase 2Completed

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Study sponsor: Vogenx, Inc. · VOGX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-05-01Actual
Enrollment · participants15Actual
Source updated2026-11-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Adverse Events Description: Number of participants with adverse events Time frame: Through study completion, 43 days Measure: Vital Signs Description: Number of participants with abnormal vital signs Time frame: Through study completion, 43 days Measure: Laboratory Tests Description: Number of participants with abnormal laboratory tests Time frame: Through study completion, 43 days Measure: Glucose nadir after dosing Description: Time course of glucose concentrations during MMTT Time frame: 0-3 hours following liquid meal. After: Measure: Glucose Nadir Description: Each participant was treated for 7 days with either placebo or the indicated dose and regimen of mizagliflozin in a cross-over fashion. At the end of each 7 day treatment period participants were administered a mixed meal tolerance test. Glucose nadirs were derived from MMTT data for placebo and each mizagliflozin dose. Time frame: 0-3 hours following MMTT.

Check registry source

· 2 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview